We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Corcept (CORT) Posts OS Data from Phase II Ovarian Cancer Study
Read MoreHide Full Article
Corcept Therapeutics Incorporated (CORT - Free Report) announced overall survival (“OS”) data from a phase II study evaluating its lead pipeline candidate, relacorilant, in combination with nab-paclitaxel for treating patients with recurrent platinum-resistant ovarian cancer.
Data from the study showed that women who received treatment with relacorilant plus nab-paclitaxel experienced 33% reduction in risk of death as compared to women treated with nab-paclitaxel alone.
Also, the median OS was 13.9 months for women who received relacorilant plus nab-paclitaxel versus 12.2 months for women receiving nab-paclitaxel monotherapy.
The company plans to begin a phase III study in the second quarter of 2022.
Shares of Corcept have rallied 22.1% so far this year against the industry’s decline of 12.4%.
Image Source: Zacks Investment Research
Corcept is also evaluating relacorilant in combination studies for treating other cancer indications.
Enrollment is also ongoing in the phase Ib study evaluating relacorilant in combination with Merck’s (MRK - Free Report) PD-1 checkpoint inhibitor, Keytruda (pembrolizumab), for treating patients suffering from adrenal cancer along with cortisol excess.
Merck’s biggest revenue generator, Keytruda, is approved for treating several types of cancer indications. Merck is studying Keytruda for addressing yet more cancer indications.
Relacorilant, is also being evaluated in phase III of the GRACE study to treat Cushing’s syndrome. The company plans to submit a new drug application for relacorilant in the second quarter of 2023. Meanwhile, enrollment is underway in the phase III study of GRADIENT, evaluating relacorilant in patients whose Cushing’s syndrome is caused by adrenal adenoma.
Successful development of relacorilant for additional indications will be a boost to the company.
Corcept’s only marketed drug, Korlym, has been approved for the once-daily oral treatment of hyperglycemia — secondary to hypercortisolism — in adult patients with endogenous Cushing’s syndrome who are suffering from type II diabetes or glucose intolerance, and who have already failed surgery or are unsuitable for the same.
Korlym generated sales worth $366 million in 2021, reflecting an increase of 3.4% year over year.
Onconova Therapeutics’ loss per share estimates have narrowed 35.6% for 2022 and 28% for 2023 over the past 60 days.
Earnings of Onconova Therapeutics have surpassed estimates in each of the trailing three quarters. ONTX has an average earnings surprise of 22.72%.
Corbus Pharmaceuticals’ loss per share estimates have narrowed 19.4% for 2022 and 16.2% for 2023 over the past 60 days.
Earnings of Corbus Pharmaceuticals have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. CRBP has delivered an average earnings surprise of 23.07%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Corcept (CORT) Posts OS Data from Phase II Ovarian Cancer Study
Corcept Therapeutics Incorporated (CORT - Free Report) announced overall survival (“OS”) data from a phase II study evaluating its lead pipeline candidate, relacorilant, in combination with nab-paclitaxel for treating patients with recurrent platinum-resistant ovarian cancer.
Data from the study showed that women who received treatment with relacorilant plus nab-paclitaxel experienced 33% reduction in risk of death as compared to women treated with nab-paclitaxel alone.
Also, the median OS was 13.9 months for women who received relacorilant plus nab-paclitaxel versus 12.2 months for women receiving nab-paclitaxel monotherapy.
The company plans to begin a phase III study in the second quarter of 2022.
Shares of Corcept have rallied 22.1% so far this year against the industry’s decline of 12.4%.
Image Source: Zacks Investment Research
Corcept is also evaluating relacorilant in combination studies for treating other cancer indications.
Enrollment is also ongoing in the phase Ib study evaluating relacorilant in combination with Merck’s (MRK - Free Report) PD-1 checkpoint inhibitor, Keytruda (pembrolizumab), for treating patients suffering from adrenal cancer along with cortisol excess.
Merck’s biggest revenue generator, Keytruda, is approved for treating several types of cancer indications. Merck is studying Keytruda for addressing yet more cancer indications.
Relacorilant, is also being evaluated in phase III of the GRACE study to treat Cushing’s syndrome. The company plans to submit a new drug application for relacorilant in the second quarter of 2023. Meanwhile, enrollment is underway in the phase III study of GRADIENT, evaluating relacorilant in patients whose Cushing’s syndrome is caused by adrenal adenoma.
Successful development of relacorilant for additional indications will be a boost to the company.
Corcept’s only marketed drug, Korlym, has been approved for the once-daily oral treatment of hyperglycemia — secondary to hypercortisolism — in adult patients with endogenous Cushing’s syndrome who are suffering from type II diabetes or glucose intolerance, and who have already failed surgery or are unsuitable for the same.
Korlym generated sales worth $366 million in 2021, reflecting an increase of 3.4% year over year.
Zacks Rank & Stocks to Consider
Corcept currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in the same sector are Onconova Therapeutics, Inc. and Corbus Pharmaceuticals Holdings, Inc. (CRBP - Free Report) , both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Onconova Therapeutics’ loss per share estimates have narrowed 35.6% for 2022 and 28% for 2023 over the past 60 days.
Earnings of Onconova Therapeutics have surpassed estimates in each of the trailing three quarters. ONTX has an average earnings surprise of 22.72%.
Corbus Pharmaceuticals’ loss per share estimates have narrowed 19.4% for 2022 and 16.2% for 2023 over the past 60 days.
Earnings of Corbus Pharmaceuticals have surpassed estimates in three of the trailing four quarters and missed the same on the other occasion. CRBP has delivered an average earnings surprise of 23.07%.